Greatmark Investment Partners Inc. increased its stake in shares of Core Laboratories N.V. (NYSE:CLB) by 1.2% during the second quarter, Holdings Channel reports. The institutional investor owned 8,607 shares of the oil and gas company’s stock after buying an additional 105 shares during the period. Greatmark Investment Partners Inc.’s holdings in Core Laboratories N.V. were worth $872,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Gulf International Bank UK Ltd increased its stake in shares of Core Laboratories N.V. by 3.1% in the first quarter. Gulf International Bank UK Ltd now owns 13,449 shares of the oil and gas company’s stock valued at $1,553,000 after buying an additional 400 shares in the last quarter. BTIM Corp. increased its stake in shares of Core Laboratories N.V. by 6.3% in the first quarter. BTIM Corp. now owns 77,224 shares of the oil and gas company’s stock valued at $8,921,000 after buying an additional 4,544 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Core Laboratories N.V. by 156.2% in the first quarter. Goldman Sachs Group Inc. now owns 68,823 shares of the oil and gas company’s stock valued at $7,951,000 after buying an additional 41,955 shares in the last quarter. Comerica Securities Inc. increased its stake in shares of Core Laboratories N.V. by 22.5% in the first quarter. Comerica Securities Inc. now owns 2,529 shares of the oil and gas company’s stock valued at $292,000 after buying an additional 465 shares in the last quarter. Finally, Morgan Stanley increased its stake in shares of Core Laboratories N.V. by 17.5% in the first quarter. Morgan Stanley now owns 167,465 shares of the oil and gas company’s stock valued at $19,346,000 after buying an additional 24,929 shares in the last quarter.

Core Laboratories N.V. (CLB) opened at 99.98 on Tuesday. The stock’s 50 day moving average is $102.90 and its 200 day moving average is $109.93. Core Laboratories N.V. has a 12 month low of $96.30 and a 12 month high of $125.83. The company has a market cap of $4.41 billion, a PE ratio of 61.34 and a beta of 1.60.

Core Laboratories N.V. (NYSE:CLB) last announced its earnings results on Monday, July 24th. The oil and gas company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.51 by $0.01. The firm had revenue of $163.90 million for the quarter, compared to the consensus estimate of $168.23 million. Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. The business’s quarterly revenue was up 10.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.35 EPS. Equities analysts predict that Core Laboratories N.V. will post $2.09 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, August 14th. Shareholders of record on Monday, July 17th will be given a $0.55 dividend. The ex-dividend date of this dividend is Thursday, July 13th. This represents a $2.20 annualized dividend and a yield of 2.20%. Core Laboratories N.V.’s dividend payout ratio is 134.15%.

ILLEGAL ACTIVITY WARNING: “Greatmark Investment Partners Inc. Buys 105 Shares of Core Laboratories N.V. (NYSE:CLB)” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/08/greatmark-investment-partners-inc-buys-105-shares-of-core-laboratories-n-v-nyseclb.html.

Several analysts recently issued reports on CLB shares. Loop Capital upgraded Core Laboratories N.V. from a “hold” rating to a “buy” rating and increased their price target for the company from $125.00 to $130.00 in a report on Friday, April 21st. Zacks Investment Research cut shares of Core Laboratories N.V. from a “buy” rating to a “hold” rating in a research report on Friday, June 23rd. BidaskClub raised shares of Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. ABN Amro raised shares of Core Laboratories N.V. to a “hold” rating in a research report on Friday, April 21st. Finally, Morgan Stanley reissued an “overweight” rating and issued a $130.00 price objective (down from $150.00) on shares of Core Laboratories N.V. in a research report on Wednesday, June 21st. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $117.17.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.